C a H Managment Company, LLC
C a H Managment Company, LLC was paid $9.81M by Medicaid between Apr 2018 and Dec 2024, across 22 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 46% of everything it billed.
33Billing provider infoC A H MANAGMENT COMPANY, LLC
KNOXVILLE, TN 37922
KNOXVILLE, TN 37922
33aNPI1447769807assigned 09/28/2017
33bProvider typeAmbulatory Care Registered Nurse
28Total paid$9.81M
24GClaims192,187
24DCodes billed22
24AFirst – last monthApr 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,512 | $182K | |
| 2019 | 8,952 | $437K | |
| 2020 | 7,580 | $395K | |
| 2021 | 28,807 | $1.64M | |
| 2022 | 50,311 | $2.27M | |
| 2023 | 52,262 | $2.60M | |
| 2024incomplete | 40,763 | $2.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 46% | 62,898 | 58,032 | $4.52M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 30% | 30,724 | 27,907 | $2.92M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 7.5% | 30,461 | 27,834 | $736K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.8% | 11,760 | 11,055 | $668K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.8% | 5,202 | 4,842 | $375K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.8% | 32,091 | 14,356 | $277K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.5% | 8,495 | 7,415 | $245K |
| 87807 | <1% | 3,799 | 3,487 | $31K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,035 | 1,781 | $26K |
| 87430 | <1% | 887 | 660 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 560 | 503 | $5K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 327 | 292 | $5K |
10 more codes
| 87501 | <1% | 583 | $2K | |
| 81002 | <1% | 471 | $887.94 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 37 | $581.07 |
| 87420 | <1% | 195 | $521.52 | |
| 81003 | <1% | 233 | $383.81 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 664 | $106.61 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 58 | $76.33 |
| 94760 | <1% | 629 | $65.34 | |
| 94761 | <1% | 33 | $19.97 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 45 | $1.59 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGODBOLD, STEVEN (VP OF OPERSATIONS)